Kasia Averall

Kasia Averall joined Cell and Gene Therapy Catapult in November 2016, tasked with establishing
the pharmaceutical quality system for the new multiproduct, multi-collaborator ATMP manufacturing
center in Stevenage, UK. The facility was successfully licensed by the
UK MHRA in August 2018, and Kasia now leads the quality assurance
team supporting a variety of cell and gene therapy manufacturers.
Before joining Cell and Gene Therapy Catapult, Kasia worked in both
quality assurance and regulatory affairs over a range of dosage
forms. She has a degree in natural sciences (biological) from the
University of Cambridge.

Related Articles

Cell and Gene Therapies and Their GMP Requirements
Features
Cell and Gene Therapies & Their GMP Requirements

Cell and gene therapies are the latest revolution in medicine manufacturing. Unlike small molecules or traditional biotech products, these therapies introduce cells and genes into a patient to treat the underlying cause of a disease—they are living medicines.